Arcus backs TIGIT combo by offering glimpse at positive data from axed trialnews2024-11-07T12:06:55+00:00November 7th, 2024|Endpoints News|
Joe Jimenez’s latest Aditum company lines up T cell engager from Chinanews2024-11-07T12:03:51+00:00November 7th, 2024|Endpoints News|
Moderna reports $10M in first RSV sales, a slow start for new vaccinenews2024-11-07T11:30:04+00:00November 7th, 2024|Endpoints News|
Sarepta discontinues work on next-gen exon-skipping drug for Duchennenews2024-11-07T10:39:11+00:00November 7th, 2024|Endpoints News|
California voters say yes to restrictions around 340B spendingnews2024-11-06T19:58:47+00:00November 6th, 2024|Endpoints News|
Q&A: GSK’s CEO Emma Walmsley on the new Trump administration, trust, AI and Chinanews2024-11-06T18:49:02+00:00November 6th, 2024|Endpoints News|
Studies show how once-obscure DNA circles drive cancer, and maybe even how to stop themnews2024-11-06T17:07:33+00:00November 6th, 2024|Endpoints News|
CVS names Aetna head, plans more pharmacy closures as new CEO takes overnews2024-11-06T16:30:38+00:00November 6th, 2024|Endpoints News|
MacroGenics pauses development of ADC; Cellectis deprioritizes CAR-Tnews2024-11-06T15:34:31+00:00November 6th, 2024|Endpoints News|
Biotech industry worries over potential for RFK Jr. ally as FDA picknews2024-11-06T15:00:20+00:00November 6th, 2024|Endpoints News|
